BofA lowered the firm’s price target on Acumen (ABOS) to $9 from $10 and keeps a Buy rating on the shares, citing the updated cash position following a Q2 report the firm calls “(understandably) quiet.” The “key update” was the phase 2 ALTITUDE-AD of sabirnetug in early AD remains on track to read-out late 2026, the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS: